ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Adobe Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ADBE

NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds behalf of purchasers of common stock of Adobe Inc. (NASDAQ: ADBE) between July 23, 2021 and September 15, 2022, both dates inclusive (the "Class Period"), of the important December 19, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Adobe common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Adobe class action, go to https://rosenlegal.com/submit–form/?case_id=20021 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 19, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, Defendants falsely downplayed competition from Figma, which provides a simple web–based tool for designing user interfaces, and misleadingly suggested that Adobe's existing offerings were adequate to counter any harms the Company may have otherwise faced due to Figma's growing market position. As a result, certain statements were materially false and misleading because they failed to disclose that: (1) Figma was growing its market share and was becoming a leader in user experience design; (2) Figma was in direct competition with Adobe on user experience design; (3) Adobe's product "Express" was not an effective counter to Figma's growing market share in bringing new customers to Adobe's paid offerings; (4) Adobe's other offerings were not succeeding in competing with Figma on user experience design; and (5) Adobe was losing market share to Figma. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Adobe class action, go to https://rosenlegal.com/submit–form/?case_id=20021 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8982448)

Fortrea kündigt KI-gestützte Partnerschaft mit Medidata zur Erhöhung der Diversität in klinischen Studien an

DURHAM, North Carolina, Nov. 20, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), ein weltweit fhrendes Auftragsforschungsinstitut (CRO), hat heute eine Partnerschaft mit Medidata, einem Unternehmen von Dassault Systmes und fhrenden Anbieter von Lsungen fr klinische Studien in der Biowissenschaftsbranche, bekanntgegeben, im Rahmen derer Medidata AI Intelligent Trials genutzt werden soll, um den Zugang zu unterschiedlichen Patienten in den von Fortrea durchgefhrten klinischen Studien zu verbessern.

Fortreas Nutzung von Medidata AI baut auf einer bestehenden Zusammenarbeit zwischen den beiden Unternehmen auf und erweitert Fortreas Einsatz von Medidata Rave EDC, einem fortschrittlichen, robusten und sicheren EDC–System fr die Erfassung und Verwaltung von klinischen Prfzentren, Patienten– und Labordaten. Fortrea wird die Funktionen von Medidata AI Intelligent Trials, einschlielich Daten zur Studiendurchfhrbarkeit und zur Diversitt, nutzen, um aufstrebende und groe biopharmazeutische Unternehmen sowie Medizinprodukte– und Diagnostikunternehmen dabei zu untersttzen, Rekrutierungsziele zu erreichen, die die von der jeweiligen Krankheit oder dem jeweiligen Zustand am strksten betroffenen Bevlkerungsgruppen widerspiegeln.

"Die Daten– und Schnittstellenkapazitten von Medidata werden unsere Fhigkeit verbessern, unterschiedliche Bevlkerungsgruppen nahtlos in den Prozess klinischer Studien einzubinden", so Mark Morais, COO und President of Clinical Services von Fortrea. "Wir freuen uns sehr ber die Zusammenarbeit mit Medidata als Teil der zukunftsweisenden Datenstrategie von Fortrea."

"Fortrea und Medidata teilen das Engagement, die Forschung im Bereich klinischer Studien voranzutreiben, und diese Partnerschaft wird die Landschaft der Diversitt in klinischen Studien weltweit neu gestalten", so Fareed Melhem, SVP, Medidata AI. "Gemeinsam untersttzen unsere Lsungen Kunden aus dem Bereich der Biowissenschaften dabei, Studienzeiten zu verkrzen und die Vorteile klinischer Therapien einem breiteren Spektrum von Patienten zugnglich zu machen."

ber Fortrea

Fortrea (Nasdaq: FTRE) ist ein weltweit fhrender Anbieter von Lsungen fr die klinische Entwicklung und den Patientenzugang in der Biowissenschaftsbranche. Wir arbeiten mit aufstrebenden und groen biopharmazeutischen, medizintechnischen und diagnostischen Unternehmen zusammen, um Innovationen im Gesundheitswesen voranzutreiben, die lebensverndernde Therapien fr bedrftige Patienten beschleunigen. Fortrea bietet Management von klinischen Studien der Phasen I–IV, klinische Pharmakologie, differenzierte technologiegesttzte Studienlsungen und Dienstleistungen nach der Zulassung. Die Lsungen von Fortrea basieren auf drei Jahrzehnten Erfahrung in mehr als 20 Therapiegebieten, einer Leidenschaft fr wissenschaftliche Strenge, auergewhnlichen Erkenntnissen und einem starken Netzwerk von Prfzentren. Unser talentiertes und vielseitiges Team von rund 19.000 Mitarbeitern in ber 90 Lndern ist so skaliert, dass wir unseren Kunden weltweit zielgerichtete und flexible Lsungen anbieten knnen. Erfahren Sie mehr darber, wie Fortrea zu einer transformativen Kraft von der Pipeline bis zum Patienten wird unter Fortrea.com und folgen Sie uns auf LinkedIn und X (ehemals Twitter) @Fortrea.

Kontakt zu Fortrea:
Jennifer Minx (Medien) "" 919–410–4195, media@fortrea.com
Kate Dillon (Medien) "" 646–818–9115, kdillon@prosek.com
Hima Inguva (Investoren) "" 877–495–0816, Investors@fortrea.com


GLOBENEWSWIRE (Distribution ID 8981987)

Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced a partnership with Medidata, a Dassault Systmes company and leading provider of clinical trial solutions to the life sciences industry, to use Medidata AI Intelligent Trials to increase access to diverse patients in clinical trials conducted by Fortrea.

Fortrea's use of Medidata AI builds on an existing collaboration between the two companies, expanding on Fortrea's use of Medidata Rave EDC, an advanced, robust, and secure EDC system for clinical trial site, patient and lab data capture and management. Fortrea will leverage features of Medidata AI Intelligent Trials, including study feasibility and diversity data, to help emerging and large biopharmas, as well as medical device and diagnostic companies, achieve enrollment goals that reflect the populations most impacted by each disease or condition under study.

“Medidata's data and interface capabilities will enhance our ability to seamlessly integrate diverse populations into the clinical trial process," said Fortrea COO and President of Clinical Services Mark Morais. "We are thrilled to work with Medidata as part of Fortrea's go–forward data strategy."

"Fortrea and Medidata share a commitment to advancing clinical trial research and this partnership is poised to reshape the landscape of diversity in clinical trials globally," said Fareed Melhem, SVP, Medidata AI. "Together, our solutions support customers in life sciences to accelerate study timelines and make the benefits of clinical therapies more accessible to a diverse spectrum of individuals."

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I–IV clinical trial management, clinical pharmacology, differentiated technology–enabled trial solutions and post–approval services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of approximately 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Jennifer Minx (Media) "" 919–410–4195, media@fortrea.com
Kate Dillon (Media) "" 646–818–9115, kdillon@prosek.com
Hima Inguva (Investors) "" 877–495–0816, Investors@fortrea.com


GLOBENEWSWIRE (Distribution ID 8981816)

Fortrea annonce un partenariat avec Medidata basé sur l’IA afin d’accroître la diversité dans les essais cliniques

DURHAM, Caroline du Nord, 20 nov. 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE), l'un des plus grands organismes de recherche sous contrat ( ORC ) au monde, a annonc aujourd'hui un partenariat avec Medidata, une socit de Dassault Systmes et l'un des principaux fournisseurs de solutions d'essais cliniques pour le secteur des sciences de la vie, afin d'utiliser les essais de Medidata bass sur l'intelligence artificielle pour amliorer l'accs divers patients aux essais cliniques mens par Fortrea.

L'utilisation de l'IA de Medidata par Fortrea s'inscrit dans le cadre d'une collaboration dj existante entre les deux socits, en largissant l'utilisation par Fortrea de Rave EDC de Medidata, un systme EDC avanc, robuste et scuris pour la saisie et la gestion des donnes relatives aux centres d'essais cliniques, aux patients et aux laboratoires. Fortrea exploitera les fonctionnalits des essais aliments par l'IA de Medidata, y compris les donnes de faisabilit et de diversit des tudes, afin d'aider les entreprises biopharmaceutiques (qu'elles soient nouvelles ou de grande taille), ainsi que les socits proposant des dispositifs mdicaux et des diagnostics, atteindre des objectifs de participation aux tudes cliniques qui soient l'image des populations les plus impactes par chaque maladie ou situation tudie.

Les donnes et les capacits d'interface de Medidata amlioreront notre capacit intgrer de manire transparente diverses populations dans les processus d'essais cliniques , a dclar Mark Morais, directeur des oprations et prsident des services cliniques de Fortrea. Nous sommes ravis de travailler avec Medidata dans le cadre de la stratgie de Fortrea en matire de donnes.

Fortrea et Medidata partagent le mme engagement faire avancer la recherche sur les essais cliniques et ce partenariat est destin remodeler le paysage de la diversit dans les essais cliniques l'chelle mondiale , a dclar Fareed Melhem, vice–prsident principal, Medidata AI. Les solutions que nous dveloppons ensemble aident les clients spcialiss dans les sciences de la vie rduire les dlais de ralisation des tudes et rendre les bienfaits des thrapies cliniques plus accessibles un large ventail d'individus.

propos de Fortrea

Fortrea (Nasdaq : FTRE) est l'un des principaux fournisseurs mondiaux de solutions de dveloppement clinique et d'accs aux soins pour les patients dans le secteur des sciences de la vie. Nous collaborons avec des socits de renom et mergentes, spcialises dans le domaine biopharmaceutique, des dispositifs mdicaux et du diagnostic afin de stimuler l'innovation en matire de soins de sant pour acclrer la mise au point de traitements rvolutionnaires pour les patients qui en ont besoin. Fortrea propose des solutions pour la gestion d'essais cliniques de phase I IV, pour la pharmacologie clinique, pour les essais diffrencis axs sur la technologie ainsi que des services aprs approbation. Les solutions de Fortrea s'appuient sur trois dcennies d'exprience couvrant plus de 20 domaines thrapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un rseau solide de centres de recherche. Notre quipe talentueuse et diversifie d'environ 19 000 personnes travaillant dans plus de 90 pays est dimensionne pour fournir des solutions cibles et flexibles nos clients, partout dans le monde. Obtenez plus d'informations sur la manire dont Fortrea influence le changement, du pipeline au patient, sur Fortrea.com et suivez–nous sur LinkedIn et X (anciennement Twitter) @Fortrea.

Coordonnes de Fortrea :
Jennifer Minx (mdia) "" 919–410–4195, media@fortrea.com
Kate Dillon (mdia) "" 646–818–9115, kdillon@prosek.com
Hima Inguva (investisseurs) "" 877–495–0816, Investors@fortrea.com


GLOBENEWSWIRE (Distribution ID 8981987)

Fortrea Anuncia Parceria Baseada em IA com a Medidata para Aumentar a Diversidade dos Ensaios Clínicos

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE), uma organizao lder global de pesquisa por contrato (CRO), anunciou hoje uma parceria com a Medidata, uma empresa da Dassault Systmes fornecedora lder de solues de ensaios clnicos para a indstria de cincias da vida, para uso dos Medidata AI Intelligent Trials para aumento do acesso a diversos pacientes dos ensaios clnicos conduzidos pela Fortrea.

O uso da Medidata AI pela Fortrea se baseia em uma colaborao existente entre as duas empresas que expande o uso do Medidata Rave EdC, um sistema EdC avanado, robusto e seguro para a o gerenciamento e captura de dados em sites de ensaios clnicos, de pacientes e laboratrios. A Fortrea ir utilizar os recursos dos Medidata AI Intelligent Trials, incluindo dados de viabilidade e diversidade do estudo, para ajudar as biofarmas emergentes e grandes, bem como os dispositivos mdicos e empresas de diagnstico, a atingir metas de inscrio que reflitam as populaes mais impactadas por cada doena ou condio do estudo.

“Os recursos de dados e interface da Medidata iro aumentar a nossa capacidade de integrar perfeitamente as diversas populaes ao processo de testes clnicos”, disse o COO e Presidente de Servios Clnicos da Fortrea, Mark Morais. "Estamos muito contentes em trabalhar com a Medidata como parte da estratgia de avano de dados da Fortrea."

"A Fortrea e a Medidata compartilham o compromisso de avanar a pesquisa de ensaios clnicos e esta parceria est pronta para remodelar o cenrio da diversidade dos ensaios clnicos em todo o mundo", disse Fareed Melhem, SVP, Medidata AI. "Juntas, nossas solues apoiam os clientes de cincias da vida a acelerar os cronogramas de estudo e tornar os benefcios das terapias clnicas mais acessveis a uma faixa diversificado de pessoas."

Sobre a Fortrea

A Fortrea (Nasdaq: FTRE) fornecedora lder global de solues para o desenvolvimento clnico e acesso ao paciente para a indstria de cincias da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacuticas, de dispositivos mdicos e de diagnstico para impulsionar a inovao na sade que acelera terapias que mudam a vida dos pacientes que precisam delas. A Fortrea fornece gerenciamento de testes clnicos de fase I–IV, farmacologia clnica, solues de testes com tecnologia diferenciada e servios ps–aprovao. As solues da Fortrea utilizam suas trs dcadas de experincia abrangendo mais de 20 reas teraputicas, sua dedicao ao rigor cientfico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada de aproximadamente 19.000 pessoas que trabalham em mais de 90 pases dimensionada para fornecer solues focadas e geis para clientes de todo o mundo. Saiba mais sobre como a Fortrea est se tornando uma fora transformadora de pipeline para paciente na Fortrea.com e siga–nos no LinkedIn e X (antigo Twitter) @Fortrea.

Contatos da Fortrea:
Jennifer Minx (Mdia) "" 919–410–4195, media@fortrea.com
Kate Dillon (Mdia) "" 646–818–9115, kdillon@prosek.com
Hima Inguva (Investidores) "" 877–495–0816, Investors@fortrea.com


GLOBENEWSWIRE (Distribution ID 8981987)

Will the UN Ever be Able to Eradicate Systemic Racism Within?

Credit: UN Staff News

By Shihana Mohamed
NEW YORK, Nov 20 2023 – In the midst of the Israel-Hamas conflagration, a significant anniversary at the United Nations –October 24th was the 78th year since its founding–went unremarked by the larger world. But the work of–and significant problems with–the UN continues. Among the problems is embedded institutional racism. It’s time that it be deeply addressed–not just by lip service.

The UN was founded in the aftermath of World War II to prevent the recurrence of such catastrophic events, with a commitment to “reaffirm faith in fundamental human rights, the dignity, and worth of the human person” and, proclaiming “the right of everyone to enjoy all human rights and fundamental freedoms, without distinction as to race, sex, language or religion.”

Marking International Day on Eliminating Racial Discrimination on March 21, 2023, the UN Secretary-General António Guterres said, “Racial discrimination is a deeply damaging and pervasive abuse of human rights and human dignity that affects every country. It is one of the most destructive forces dividing societies, responsible for death and suffering on a grotesque scale throughout history. Today, racial discrimination and the legacies of enslavement and colonialism continue to ruin lives, marginalize communities and limit opportunities, preventing billions of people from achieving their full potential.”

There are visible contradictions in how the UN addresses racism and racial discrimination that go against the stipulations of the UN Charter. Some of this is attributable to systemic issues that date back to the founding of the UN.

The UN was established in 1945 as a solution for countries of European descent as they looked for a stable new international (and European) order. At that time, most parts of the world remained under European colonial domination, so the creation of the UN was led by those colonial and former enslaving powers.

The wave of decolonization between 1945 and 1960 changed the face of the world order as well as the World Body. The membership of the UN grew from 51 founding members in 1945 to 127 by 1970, and currently there are 193 member states. This aspect contributed towards altering the balance of power within the UN. These new member states were not from Europe and not white.

These new members persuaded the UN to embrace the change in the world order and brought new ideas to the General Assembly, the main deliberative body of the UN, which now practices the noble principle of “One Nation One Vote” and with five Regional Groups of member states – Africa, Asia – Pacific, Eastern Europe, Latin America and the Caribbean, and Western Europe and Other Group (including North America).

However, a similar transformation did not take place within the staffing of the organizations of the UN system.

In UN organizations, the staff experience or witness workplace discrimination largely on the basis of national origin, race, or skin color, according to the findings of several recent surveys. Most mentioned their lack of trust and confidence in the system, including existing recourse mechanisms and believed that the organization would offer no recourse if they complained about the racism they experienced.

The JIU review on racism and racial discrimination confirms that racism and racial discrimination are widespread throughout the system and the magnitude is high, based on evidence of prevalence, form, and effects of racism and racial discrimination. It further revealed that the “likelihood of experiencing racism and racial discrimination is higher” among black/African descent, Indigenous, South Asian and Middle Eastern/North African respondents.

The review of the JIU found that one in every five surveyed respondents (20 per cent) had experienced racial discrimination or harassment while the 2020 UN Secretariat survey on racism found that one in every three respondents (33 per cent) had experienced discrimination. The recently released findings of the survey conducted by the UN Asia Network for Diversity and Inclusion (UN-ANDI) revealed that three in every five respondents (61 per cent) experienced racism and bias, as well as the distress caused to them in terms of health, career and well-being.

More than half of the staff in the Professional and higher categories in the UN organizations are from Western countries or European descent. Hence, there is disproportionate representation among the five regional groupings. This disparity, directly and indirectly, contributes to the current organizational culture that enables racism and racial discrimination.

All organizations in the UN system should implement measures to reduce the proportion of the most highly represented regional groups and to increase the proportion of less represented regional groups, thereby reducing the overall imbalance among regional groups and making the UN organizations more representative of the populations they serve, including at decision-making levels.

Tackling systemic racism and racial discrimination within the UN system is not only an ethical issue but also a business issue. Racism and racial discrimination cause significant financial losses for all parties. Staff members suffer from loss of income, health, morale, enthusiasm and job satisfaction during their career span, while organizations suffer in terms of loss of time, resources, talent, committed staff, quality of work, timely delivery, productivity and reputation, among others.

It is therefore important to assess the tangible impacts of racism, in monetary terms, on staff, organizations and their capacities for programme delivery, especially the implementation of the Sustainable Development Goals. Such an exercise is critical if the UN organizations are genuinely committed to eliminating racism within.

The world urgently needs the UN leadership to fight systemic racism. Hence, the organizations of the UN system do not have time to spend another year on internal discussions and dialogues. Immediate implementation of the Secretary-General’s Strategic Action Plan on Addressing Racism and Promoting Dignity for All in the UN Secretariat would be a starting point, and similar action plans should follow urgently in all other UN organizations.

The time is now for the UN to act to fully eradicate racism and racial discrimination within its organizations.

Shihana Mohamed, a Sri Lankan national, is a founding member and one of the Coordinators of the United Nations Asia Network for Diversity and Inclusion (UN-ANDI) and a Public Voices Fellow with The OpEd Project and Equality Now.

UN-ANDI is a global network of like-minded Asians of the United Nations system who strive to promote a more diverse and inclusive culture and mindset within the UN system. UN-ANDI is the first-ever effort to bring together a diverse group of personnel (staff, retirees, consultants, interns, diplomats, and others) from Asia and the Pacific (nationality/origin/descent) in the UN system. Please contact via email at UnitedNationsAsiaNetwork@gmail.com to connect or/and collaborate with UN-ANDI.

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Axi lança a campanha “Escolha o seu Diferencial” com estrelas do Manchester City

SYDNEY, Australia, Nov. 20, 2023 (GLOBE NEWSWIRE) — A principal corretora online de FX e CFDs, Axi, lanou sua nova campanha, “Escolha o seu Diferencial”. Apresentando estrelas do Manchester City FC, a campanha introduz o novo programa de alocao de capital da Axi, o Axi Select.

Desde 2020, a Axi, parceira oficial de operao online do Manchester City, tem utilizado seu acesso aos jogadores do clube para oferecer contedo interativo e destacar suas ofertas nicas. Neste ano, as estrelas do Manchester City, Erling Haaland, Kyle Walker e Rodri, competem cara a cara pelas vantagens em vrios desafios, como classificao de bolas e construo de torres.

Hannah Hill, Chefe de Marca e Patrocnio da Axi, expressou seu entusiasmo pela nova campanha, afirmando: “Como acontece todos os anos, trabalhar com os jogadores do City foi, mais uma vez, muito empolgante. Eles demonstraram uma qumica incrvel entre si, o que resultou em timas brincadeiras e contedo incrvel. A colaborao foi uma maneira nica de apresentar a nossa mais recente oferta, o Axi Select. Com nosso novo programa, nossos clientes podem acessar o diferencial competitivo de que precisam para se tornarem traders profissionais.”

Em setembro, a corretora lanou com orgulho seu novo programa de alocao, o Axi Select. Com o objetivo de capacitar operadores ambiciosos e facilitar sua progresso para a negociao profissional, o programa oferece aos operadores a oportunidade de acessar financiamento de capital de at US$ 1.000.000, alm de outros benefcios excepcionais, sem taxas de registro e a chance de ganhar at 90% de seus lucros.

Ao falar sobre o Axi Select em seu lanamento, Louis Cooper, diretor comercial da Axi, disse: “Na Axi, temos orgulho de ser uma marca que sempre traz o que h de melhor para nossos clientes. Nossa nova e revolucionria oferta, Axi Select, a primeira de seu tipo entre os corretores e outro reflexo verdadeiro da promessa de nossa marca. Com a Axi Select, oferecemos oportunidades inigualveis aos nossos traders, redefinindo os limites do que possvel na negociao e remodelando a evoluo do setor financeiro.”

Para obter mais informaes sobre o Axi Select, visite https://www.axi.com/int/funded–trader–programme

Veja este vdeo https://www.youtube.com/watch?v=eDZeNJGi_UU

Sobre a Axi

Axi uma corretora global de negociao on–line de FX e CFDs. Como corretora preferida de milhares de clientes ambiciosos em mais de 100 pases em todo o mundo, ajudamos todos os tipos de traders, empresas de trading, bancos e organizaes financeiras a encontrar o diferencial de que precisam para atingir suas metas financeiras atravs de transaes conscientes feitas nos mercados financeiros mundiais. A Axi oferece uma ampla gama de ativos, incluindo CFDs para diversas classes de ativos, como Forex, aes, petrleo, metais preciosos, caf, ndices e outras commodities.

Confira outras comunicaes da Axi em https://www.axi.com/int/blog/company–news


GLOBENEWSWIRE (Distribution ID 1000900242)

Axi launches Select Your Edge campaign with Manchester City stars

SYDNEY, Australia, Nov. 20, 2023 (GLOBE NEWSWIRE) — Leading online FX and CFD broker Axi has launched their new campaign, Select Your Edge. Featuring stars of Manchester City FC, the campaign introduces Axi's new capital allocation programme, Axi Select.

Since 2020, Axi, the Official Online Trading Partner of Manchester City, has utilised their access to the club's players to deliver engaging content and to highlight their unique offerings. This year, Manchester City stars Erling Haaland, Kyle Walker, and Rodri compete head–to–head for the edge in various challenges such as ball–sorting and tower building.

Hannah Hill, Head of Brand and Sponsorship at Axi, expressed her enthusiasm for their new campaign, stating, "As with every year, working with the City players was, once again, very exciting. They displayed amazing chemistry with each other, and this made for some great banter and amazing content. The collaboration was a unique way to introduce our latest offering, Axi Select. With our new programme, our clients can access the competitive edge they need to become pro traders."

In September, the broker proudly launched their new capital allocation programme, Axi Select. Aimed to empower ambitious traders and facilitate their progression into professional trading, the programme offers traders the opportunity to access capital funding up to $1,000,000 USD, as well as other exceptional advantages including zero registration fees, and the potential to earn up to 90% of their profits.

Talking about Axi Select when it debuted, Louis Cooper, Chief Commercial Officer at Axi, said, "At Axi, we take pride in being a brand that consistently brings the edge to life for our customers. Our revolutionary new offering, Axi Select, is the first–of–its–kind among brokers and another true reflection of our brand promise. With Axi Select, we deliver unparalleled opportunities to our traders whilst both redefining the boundaries of what's possible in trading and reshaping the evolution of the financial industry."

For more information about Axi Select, visit https://www.axi.com/int/funded–trader–programme.
Watch video https://www.youtube.com/watch?v=eDZeNJGi_UU

About Axi

Axi is a global online FX and CFDs trading broker. As the preferred broker for thousands of ambitious customers in over 100 countries worldwide, we help all types of traders, trading businesses, banks and financial organizations find the edge they need to achieve their financial goals through informed transactions made on the world's financial markets. Axi offers a comprehensive range of assets including CFDs for several asset classes such as Forex, Shares, Oil, Precious Metals, Coffee, Indices, and other commodities.

For other Axi communications, visit https://www.axi.com/int/blog/company–news


GLOBENEWSWIRE (Distribution ID 1000900242)

Australia: Reconciliation Back to Square One?

Credit: Jenny Evans/Getty Images

By Inés M. Pousadela
MONTEVIDEO, Uruguay, Nov 20 2023 – Australia had the chance to take a step forward in redressing the exclusion of its Indigenous people – and chose not to. In a referendum held in October, voters rejected a constitutional amendment to establish an institution for Indigenous people to have a say on matters that concern them.

On a 90 per cent turnout under mandatory voting, 60 per cent voted against. Supporters of the referendum were left pointing the finger at disinformation – and those who pushed it for political gain.

A history of exclusion

For a long time, Indigenous Australians – currently 3.8 per cent of the country’s population – lacked any recognition. European settlers didn’t see any need for a treaty with the people already there. Indigenous Australians only got the vote in 1962 and, following a referendum, were put on the census as late as 1972 – until then, they literally didn’t count. They remain unrecognised in the country’s constitution.

For most of the 20th century, assimilation laws saw Indigenous children forcibly taken from their families on a mass scale. It’s estimated that between 1910 and 1970 10 to 30 per cent of Indigenous children were handed to childless white couples to be raised as white. The horror of the ‘stolen generations’ only began to be acknowledged in the mid-1990s.

In 1997 the Australian Human Rights Commission issued a report with recommendations for healing and reconciliation. But a belated prime ministerial apology came only in 2008. That same year, the government issued a plan to reduce disadvantage among Indigenous people. After most of its targets expired unmet, a new approach was developed in partnership with an Indigenous coalition in 2020.

But little progress has been made in overcoming exclusion. On almost any indicator, Indigenous people remain two to three times worse off than non-Indigenous Australians. Being dramatically underrepresented in decision-making bodies, they also lack the tools to change it.

The Uluru Statement from the Heart

The road towards the referendum started more than a decade ago, when an expert panel found that constitutional recognition was the way to go. But the call for a referendum was delayed. In 2016, a Referendum Council again concluded that constitutional reform should proceed.

In 2017, the First Nations Dialogues issued the Uluru Statement from the Heart, which called for a Voice to Parliament for Indigenous people, a truth commission and a treaty. The Voice was viewed as the first step to open up a conversation and enable further progress.

Then-Prime Minister Malcolm Turnbull, of the centre-right Liberal Party, rejected the Uluru Statement. But in 2018 another committee was set up to investigate options for constitutional change – and again, it endorsed a constitutionally enshrined Voice. The Labor opposition promised to put the proposal to a referendum if it won the next election.

Political change: potential and limitations

The Liberal/National coalition lost the May 2022 election, and Labor’s incoming prime minister Anthony Albanese promised progress on long-stalled policies to address Indigenous rights.

The proposed constitutional amendment and text of the ballot question were made public in March 2023 and approved by parliament in June. The government endorsed a set of principles of representation, transparency and accountability that would be used to design the Voice. It was made clear that, as the name implied, this new body would give a voice to Indigenous people but not have decision-making authority or veto power. Any further decision on its composition, functions, powers and procedures would be in the hands of parliament.

Foreshadowing what was to come, the Liberal and National opposition parties submitted dissenting reports, and the Nationals rejected the proposal entirely. By siding with the No campaign, the opposition doomed the referendum. No referendum has ever been carried without bipartisan support.

For and against

Given the legal requirement to distribute an official pamphlet presenting the case for both sides, members of parliament who’d voted for and against the amendment bill drafted and approved a text containing their side’s arguments. This meant that disinformation was inserted into the process from the start: as an independent fact-checking initiative showed, several claims in the No pamphlet were false or misleading.

The Yes campaign focused its messaging on fairness, reconciliation and healing, seeking to sell the idea that Australia would be made better by the recognition of a space for Indigenous people to have a say in national politics.

Indigenous people overwhelmingly supported the proposal, although some opposed it – because they thought it didn’t go far enough, saw it as whitewash or hoped not to see relationships they’d painstakingly developed sidelined. The No campaign made a point of foregrounding contrarian Indigenous voices, disproportionately boosted by supportive media.

Different organisations in the No camp appealed to different groups. Advance, a conservative lobby group, went after young progressives with its ‘Not Enough’ campaign, suggesting that the Voice wasn’t what Indigenous Australians wanted and wouldn’t solve their problems. The Blak Sovereign Movement questioned the timing, arguing that a treaty should be negotiated first. Disinformation and racial abuse were rife.

Two much-repeated claims were that the Voice would divide Australians and enshrine privileges for Indigenous people. No campaigners peddled a zero-sum idea: that non-Indigenous people would lose if Indigenous people won. They falsely claimed that people would lose their farms or that Indigenous people would charge them to access beaches.

Another fear-stoking argument was that the Voice was only the beginning – after they secured this, Indigenous people would go for more, until they took everything from the rest. It could, for example, open up a conversation about land rights. That may have been a genuine fear for Australia’s powerful extractive industries, explaining why the right-wing think tanks that have consistently opposed climate action also lobbied against the Voice.

Having sowed disinformation and confusion, the No campaign told voters that, if in doubt, they should play it safe and vote no. It worked.

What next?

The result could bring even greater backlash. Emboldened, some opposition politicians have since withdrawn their previously stated support for a treaty and suggested rolling back practices they now present as inadmissible concessions to identity politics. This could be a harbinger for the opposition pinning its comeback hopes on a culture war strategy.

But while the referendum defeat has dealt a hard blow to hopes of challenging the exclusion of Indigenous Australians, it isn’t quite game over. A specific proposal has been defeated, but there’s plenty left to advocate for. Progress on the wider reconciliation agenda, including other forms of recognition and redress, could still be possible, particularly at state and local levels. The Uluru Statement from the Heart remains the compass, and civil society will keep urging politicians and the public to follow its path.

Inés M. Pousadela is CIVICUS Senior Research Specialist, co-director and writer for CIVICUS Lens and co-author of the State of Civil Society Report.

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

OPEN Health unites patient engagement experts to transform the patient experience

London, Nov. 20, 2023 (GLOBE NEWSWIRE) — London, UK "" November 20, 2023 "" OPEN Health, a preeminent global provider of consulting, HEOR and market access, patient engagement, and scientific and creative communications services, is bringing together experts in strategic patient innovation and engagement, deepening the organization's existing commitment to building patient–first solutions.

OPEN Health is combining the strength, expertise, and proven track record of the Px Group, a division of the CM Group which was acquired in 2022, and OPEN Health's own patient engagement team into a unified global patient communications, patient research, and creative patient engagement partner. The combined team will be led by Cherie Myatt, alongside Senior Vice President Alexandra Dubois, Registered Health Psychologist and Cognitive Behavioral Therapist Dr. Sumira Riaz, and Patient Centricity Global Lead Gavin Jones.

Myatt, co–founder of the CM Group, started to build out a patient engagement team in 2016 based on clients' needs to connect and activate their patient communities. She and Dubois, an experienced marketer and rare disease advocate, launched a division of the agency focused exclusively on providing patient engagement solutions to clients in the life sciences industry, particularly those in rare and complex conditions. Dr. Sumira Riaz has led OPEN Health's Patient Engagement practice in Europe for the past six years, with an industry–leading team of health psychologists and behavioral scientists.

"I am excited to bring together our global experts to focus on engagement with patients, caregivers, community leaders, and advocacy groups. Together, we will use the patient voice to improve life–changing treatments across the globe," said Myatt, whose title is President of OPEN Health Patient Engagement.

Dr. Annemarie Clegg, Chief Medical Officer at OPEN Health, commented, "By working as one, united team, we can better leverage our respective talents and methodologies to unlock patient engagement opportunities across the product life cycle and drive more effective engagement solutions."

Collaborating with more than 1,300 global OPEN Health experts, the Patient Engagement team provides a wide range of solutions to address specific challenges for clients. Its full suite of solutions includes:

  • Strategy, insights & market research "" delivers design solutions that resonate with communities and significantly impact disease outcomes with a profound understanding of patient needs.
  • Health psychology & behavioral science "" delivers comprehensive insights into the lived experience of patient and caregiver with evidence–based methodologies.
  • Patient content & storytelling "" delivers patient–focused communications and storytelling solutions that educate, connect, and inspire.
  • Patient Engager programs and advocacy engagement "" partners with life sciences companies and their patients and caregiver communities to purposefully infuse the patient perspective into programs and communications.

To learn more, visit https://www.openhealthgroup.com/patient–engagement

About OPEN Health

OPEN Health unites deep scientific knowledge with wide–ranging specialist expertise to unlock possibilities that improve health outcomes and patient well–being. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across consulting, HEOR and market access, scientific communications, patient engagement, and creative omnichannel communications. For more information on OPEN Health, visit www.openhealthgroup.com.

Press contact:

OPEN Health

Candice Subero, Vice President, Global Marketing

candicesubero@openhealthgroup.com

Attachment


GLOBENEWSWIRE (Distribution ID 8981909)